Repository logo
Home
Research Outputs
Collections
Statistics
Shared Repository Homepage
  1. Home
  2. Cultural Heritage Shared Repository Service
  3. Science Museum Group
  4. Article
  5. Pandemic drugs at pandemic speed: infrastructure for accelerating COVID-19 drug discovery with hybrid machine learning- and physics-based simulations on high-performance computers

Pandemic drugs at pandemic speed: infrastructure for accelerating COVID-19 drug discovery with hybrid machine learning- and physics-based simulations on high-performance computers

Resource type
Journal article
Creator (person)
Bhati, Agastya P.
ORCIDORCID logo
Wan, Shunzhou
ORCIDORCID logo
Alfè, Dario
Clyde, Austin R.
Bode, Mathis
Tan, Li
Titov, Mikhail
Merzky, Andre
Turilli, Matteo
Jha, Shantenu
Highfield, Roger R.
Rocchia, Walter
Scafuri, Nicola
Succi, Sauro
Kranzlmà¼ller, Dieter
Mathias, Gerald
Wifling, David
Donon, Yann
Di Meglio, Alberto
Vallecorsa, Sofia
Ma, Heng
Trifan, Anda
Ramanathan, Arvind
Brettin, Tom
Partin, Alexander
Xia, Fangfang
ORCIDORCID logo
Duan, Xiaotan
Stevens, Rick
Coveney, Peter V.
ORCIDORCID logo
Date published
December 6, 2021
Abstract
The race to meet the challenges of the global pandemic has served as a reminder that the existing drug discovery process is expensive, inefficient and slow. There is a major bottleneck screening the vast number of potential small molecules to shortlist lead compounds for antiviral drug development. New opportunities to accelerate drug discovery lie at the interface between machine learning methods, in this case, developed for linear accelerators, and physics-based methods. The two methods, each have their own advantages and limitations which, interestingly, complement each other. Here, we present an innovative infrastructural development that combines both approaches to accelerate drug discovery. The scale of the potential resulting workflow is such that it is dependent on supercomputing to achieve extremely high throughput. We have demonstrated the viability of this workflow for the study of inhibitors for four COVID-19 target proteins and our ability to perform the required large-scale calculations to identify lead antiviral compounds through repurposing on a variety of supercomputers.
Funder
Funder nameAwards
U.S. Department of Energy
JDACS4C
European Commission
Coronavirus CARES Act
U.S. Department of Energy
DOE
Office of Science
National Cancer Institute (NCI) of the National Institutes of Health
United States Department of Energy
National Nuclear Security Administration
CSGF
DE-SC0019323
Texas Advanced Computing Center
EU
823712
UCL
MRC
MR/L016311/1
Journal title
Interface Focus
Volume
11
Issue
6
Publisher
The Royal Society
eISSN
2042-8901
Official URL
https://doi.org/10.1098/rsfs.2021.0018
Rights statement
In Copyright
DOI
10.1098/rsfs.2021.0018
Managed by the British Library and supported by the AHRC

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • End User Agreement
  • About
  • Contact
  • Help
Repository logo COAR Notify